Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)

Detalles Bibliográficos
Main Authors:	Schmidt, C, Kochhar, S, Excler, J, Smith, C, McMichael, A, Hanke, T, Bwayo, J, Jaoko, W, Weber, J, Kaleebu, P, Peters, B, Pantaleo, G, Vardas, E, Vasan, S, Keefer, M, Ramanathan, V, Boyle, R, Fast, P
Formato:	Conference item
Publicado:	2008

Títulos similares

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
por: Peters, B, et al.
Publicado: (2007)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
por: Hanke, T, et al.
Publicado: (2002)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
por: Dorrell, L, et al.
Publicado: (2007)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
por: Mwau, M, et al.
Publicado: (2004)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
por: Howles, S, et al.
Publicado: (2010)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
por: Jaoko, W, et al.
Publicado: (2008)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
por: Cottingham, M, et al.
Publicado: (2008)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
por: L. F. Stovba, et al.
Publicado: (2023-04-01)

A Novel Monoclonal Antibody Against a Modified Vaccinia Ankara (MVA) Envelope Protein as a Tool for MVA Virus Titration by Flow Cytometry
por: Simeon Cua, et al.
Publicado: (2024-10-01)

Expression of an Efficient Selection Marker Out of a Duplicated Site in the ITRs of a Modified Vaccinia Virus Ankara (MVA)
por: Sirine Abidi, et al.
Publicado: (2024-12-01)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
por: Maurilia Marcacci, et al.
Publicado: (2020-07-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Lior Nave, et al.
Publicado: (2023-08-01)

Altered primary CD8+ T cell response to a modified virus Ankara(MVA)-vectored vaccine in the absence of CD4+ T cell help.
por: Estcourt, M, et al.
Publicado: (2005)

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans
por: Alina Tscherne, et al.
Publicado: (2024-11-01)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
por: Rosario, M, et al.
Publicado: (2010)

Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs
por: Busquets, N, et al.
Publicado: (2011)

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.
por: Hanke, T, et al.
Publicado: (2007)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
por: Dorrell, L, et al.
Publicado: (2000)

Notes on Transient Host Range Selection for Engineering Vaccinia Virus Strain MVA
por: David C. Tscharke, et al.
Publicado: (2002-07-01)

Clinical development of Modified Vaccinia virus Ankara vaccines.
por: Gilbert, S
Publicado: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
por: Gilbert, S
Publicado: (2013)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
por: Hanke, T, et al.
Publicado: (1998)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
por: Sharpe, S, et al.
Publicado: (2003)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
por: López-Camacho, C, et al.
Publicado: (2019)

Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay.
por: Winstone, N, et al.
Publicado: (2009)

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.
por: Slyker, J, et al.
Publicado: (2005)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
por: C. Staib, et al.
Publicado: (2000-06-01)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
por: Smith, C, et al.
Publicado: (2005)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
por: Moorthy, V, et al.
Publicado: (2003)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
por: Gilbert, S, et al.
Publicado: (1999)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
por: Schneider, J, et al.
Publicado: (1998)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
por: Caroline Staib, et al.
Publicado: (2003-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Olga Vladimirovna Orlova, et al.
Publicado: (2022-09-01)

Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
por: Ondondo, B, et al.
Publicado: (2006)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
por: McConkey, S, et al.
Publicado: (2003)

Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
por: Hanke, T, et al.
Publicado: (1999)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
por: Mingwang Shen, et al.
Publicado: (2024-10-01)

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen.
por: Allen, T, et al.
Publicado: (2000)

Isolation of vaccinia MVA recombinants using the viral F13L gene as the selective marker
por: Juana M. Sánchez-Puig, et al.
Publicado: (2005-11-01)

Erratum: Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction (Journal of General Virology (2007) vol. 88 ( 1) (1-12))
por: Hanke, T, et al.
Publicado: (2008)